89 related articles for article (PubMed ID: 22306835)
21. Ductal carcinoma in situ (DCIS). A highly treatable breast cancer.
Mayo Clin Womens Healthsource; 2009 Oct; 13(10):1-2. PubMed ID: 19727033
[No Abstract] [Full Text] [Related]
22. Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.
Kaldate R; Huston A; McCoy H; Cardeiro D; Noyes K
Breast J; 2014; 20(3):325-6. PubMed ID: 24708220
[No Abstract] [Full Text] [Related]
23. Clinical management of BRCA1 and BRCA2 mutation carriers.
Domchek SM; Armstrong K; Weber BL
Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
[No Abstract] [Full Text] [Related]
24. Large genomic rearrangements in BRCA1 and BRCA2: implications for patient care.
Mahon SM
Oncol Nurs Forum; 2013 May; 40(3):220-2. PubMed ID: 23615136
[No Abstract] [Full Text] [Related]
25. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
26. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
27. How well does supplemental screening magnetic resonance imaging work in high-risk women?
Berg WA
J Clin Oncol; 2014 Jul; 32(21):2193-6. PubMed ID: 24934782
[No Abstract] [Full Text] [Related]
28. Ductal carcinoma in situ: a rose by any other name.
Wickerham DL; Julian TB
J Natl Cancer Inst; 2013 Oct; 105(20):1521-2. PubMed ID: 24068770
[No Abstract] [Full Text] [Related]
29. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
Reynolds C; Davidson JA; Lindor NM; Glazebrook KN; Jakub JW; Degnim AC; Sandhu NP; Walsh MF; Hartmann LC; Boughey JC
Ann Surg Oncol; 2011 Oct; 18(11):3102-9. PubMed ID: 21947588
[TBL] [Abstract][Full Text] [Related]
31. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
32. Two double heterozygotes in a South African Afrikaner family: implications for BRCA1 and BRCA2 predictive testing.
Loubser F; de Villiers JN; van der Merwe NC
Clin Genet; 2012 Dec; 82(6):599-600. PubMed ID: 22486351
[No Abstract] [Full Text] [Related]
33. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
Tubbs RR; Stoler MH
Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
[No Abstract] [Full Text] [Related]
34. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
35. Not all ductal carcinoma in situ is created equal: can we avoid surgery for low-risk ductal carcinoma in situ?
Lippey J; Spillane A; Saunders C
ANZ J Surg; 2016 Nov; 86(11):859-860. PubMed ID: 27784140
[No Abstract] [Full Text] [Related]
36. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
Noh JM; Choi DH; Nam SJ; Lee JE; Kim JW; Kim SW; Kang E; Lee MH; Ahn SH; Kim KS; Park SK; Haffty BG;
Breast Cancer Res Treat; 2012 Jan; 131(1):217-22. PubMed ID: 21847643
[TBL] [Abstract][Full Text] [Related]
37. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
38. Mammographic, US, and MR imaging phenotypes of familial breast cancer.
Schrading S; Kuhl CK
Radiology; 2008 Jan; 246(1):58-70. PubMed ID: 18096529
[TBL] [Abstract][Full Text] [Related]
39. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
[TBL] [Abstract][Full Text] [Related]
40. A pictorial journey through variants of ductal carcinoma in situ (DCIS) and DCIS mimickers.
Resetkova E
Clin Breast Cancer; 2012 Oct; 12(5):347-63. PubMed ID: 23040003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]